BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12445249)

  • 1. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer.
    Sagarra RA; Andrade LA; Martinez EZ; Pinto GA; Syrjänen KJ; Derchain SF
    Int J Gynecol Cancer; 2002; 12(6):720-7. PubMed ID: 12445249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
    Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
    Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.
    Diebold J; Baretton G; Felchner M; Meier W; Dopfer K; Schmidt M; Löhrs U
    Am J Clin Pathol; 1996 Mar; 105(3):341-9. PubMed ID: 8602616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
    Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma.
    Skirnisdóttir I; Sorbe B; Seidal T
    Int J Gynecol Cancer; 2001; 11(2):147-58. PubMed ID: 11328414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
    Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
    J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DEF6 expression in ovarian carcinoma correlates with poor patient survival.
    Liew PL; Fang CY; Lee YC; Lee YC; Chen CL; Chu JS
    Diagn Pathol; 2016 Aug; 11(1):68. PubMed ID: 27488395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
    Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
    Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 and related proteins in epithelial ovarian cancer.
    Sengupta PS; McGown AT; Bajaj V; Blackhall F; Swindell R; Bromley M; Shanks JH; Ward T; Buckley CH; Reynolds K; Slade RJ; Jayson GC
    Eur J Cancer; 2000 Dec; 36(18):2317-28. PubMed ID: 11094305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer.
    Ikeda K; Sakai K; Yamamoto R; Hareyama H; Tsumura N; Watari H; Shimizu M; Minakami H; Sakuragi N
    Int J Gynecol Cancer; 2003; 13(6):776-84. PubMed ID: 14675314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.
    Pieretti M; Hopenhayn-Rich C; Khattar NH; Cao Y; Huang B; Tucker TC
    Cancer Invest; 2002; 20(1):11-23. PubMed ID: 11852993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.
    Singleton TP; Perrone T; Oakley G; Niehans GA; Carson L; Cha SS; Strickler JG
    Cancer; 1994 Mar; 73(5):1460-6. PubMed ID: 7906608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
    Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; McKee B; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):79-85. PubMed ID: 12182977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
    Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
    Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.
    Kupryjańczyk J; Szymańska T; Madry R; Timorek A; Stelmachów J; Karpińska G; Rembiszewska A; Ziółkowska I; Kraszewska E; Debniak J; Emerich J; Ułańska M; Płuzańska A; Jedryka M; Goluda M; Chudecka-Głaz A; Rzepka-Górska I; Klimek M; Urbański K; Breborowicz J; Zieliński J; Markowska J
    Br J Cancer; 2003 Mar; 88(6):848-54. PubMed ID: 12644821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.